BioLineRx (NASDAQ:BLRX) Receives “Buy” Rating from HC Wainwright

BioLineRx (NASDAQ:BLRX)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a note issued to investors on Tuesday, June 17th,Benzinga reports.

Several other research analysts have also commented on the company. Jones Trading upgraded BioLineRx from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 30th. Wall Street Zen began coverage on shares of BioLineRx in a research note on Sunday, May 18th. They set a “sell” rating for the company.

BioLineRx Stock Up 11.0%

Shares of BLRX traded up $0.44 during trading on Tuesday, reaching $4.44. The company’s stock had a trading volume of 112,722 shares, compared to its average volume of 232,216. The company has a market cap of $18.91 million, a price-to-earnings ratio of -0.50 and a beta of 1.29. The company has a quick ratio of 2.04, a current ratio of 2.27 and a debt-to-equity ratio of 0.37. The company has a fifty day moving average of $3.82 and a two-hundred day moving average of $4.46. BioLineRx has a twelve month low of $2.30 and a twelve month high of $35.60.

BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings results on Tuesday, May 27th. The biotechnology company reported $1.39 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $2.23. The firm had revenue of $11.75 million for the quarter, compared to analysts’ expectations of $7.72 million. BioLineRx had a negative net margin of 15.21% and a negative return on equity of 23.93%. On average, sell-side analysts predict that BioLineRx will post -5.8 EPS for the current fiscal year.

Institutional Trading of BioLineRx

An institutional investor recently bought a new position in BioLineRx stock. Highbridge Capital Management LLC acquired a new position in BioLineRx Ltd. (NASDAQ:BLRX) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 1,010,012 shares of the biotechnology company’s stock, valued at approximately $215,000. Highbridge Capital Management LLC owned approximately 50.50% of BioLineRx at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.